---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-063707"
form_type: "8-K"
ticker: "VKTX"
cik: "0001607678"
company_name: "Viking Therapeutics, Inc."
filed_at: "2024-05-23T23:59:59+00:00"
generated_at: "2026-06-01T09:11:39.664353+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Viking Therapeutics stockholders approve 2024 equity plans and re-elect directors at annual meeting

## Summary
- Stockholders re-elected Brian Lian (50.5M for, 17.4M withheld) and Lawson Macartney (22.3M for, 45.7M withheld) as Class III directors.
- 2024 Equity Incentive Plan approved (48.5M for, 19.3M against).
- 2024 Employee Stock Purchase Plan approved (67.1M for, 0.7M against).
- Advisory say-on-pay approved (63.2M for, 4.5M against).
- Ratification of Marcum LLP as auditor for FY2024 approved (87.4M for, 0.7M against).

## SEC filing metadata
- accession: 0000950170-24-063707
- form_type: 8-K
- ticker: VKTX
- cik: 0001607678
- company_name: Viking Therapeutics, Inc.
- filed_at: 2024-05-23T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1607678/000095017024063707/0000950170-24-063707-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1607678/000095017024063707/vktx-20240521.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-063707
- JSON: https://secwatch.observer/filing/0000950170-24-063707.json
- Plain text: https://secwatch.observer/filing/0000950170-24-063707.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.